Clinical Trial

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-10-12; most recent amendment 2025-02-19.
Status change: Not Yet Recruiting → Recruiting 2024-05-27
Trial Details
NCT Number NCT06088888
Lead Sponsor Shenzhen TargetRx Co., Ltd.
Collaborators: M.D. Anderson Cancer Center
Conditions Chronic Myelogenous Leukemia
Enrollment 90 participants
Start Date 2024-07-02
Primary Completion 2027-03-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-21